Health · Healthcare & Policy · 11 hrs ago
Brazil seeks more obesity drug options as it weighs free treatment in public health system
President Luiz Inácio Lula da Silva has promised free weight-loss injections through Brazil’s public health system.
But most semaglutide products newly approved in Brazil are formally for diabetes, not obesity, so they may not qualify for public purchases intended for weight loss.
The health ministry has asked regulator Anvisa to speed up reviews of applications and label changes for these medicines, and the agency has agreed to give them priority.
More products approved for obesity could increase competition and help lower the prices used in a public funding decision.
The government’s health technology commission, Conitec, is assessing whether to add the injections, after rejecting them three times in previous reviews.
It has 180 days to issue an opinion, with a possible 90-day extension, and the decision will help determine whether the drugs enter public care.
Brazil’s Health Ministry has asked the health regulator Anvisa to speed up reviews of obesity-drug registrations and label changes.
The request comes as the government considers providing weight-loss injections free through the public health system, known as SUS.
Most newly registered semaglutide products in Brazil are approved for diabetes, not obesity, limiting the options that could be considered for public procurement.
The health technology commission Conitec is assessing whether to add obesity injections to SUS coverage.
Health Minister Alexandre Padilha said he plans to reserve R$1.5 billion a year for treatment, while pharmaceutical industry figures have questioned whether that would be enough.
- Who
- Brazil’s Health Ministry has asked Anvisa to accelerate reviews; Conitec is assessing public coverage.
- What
- The government is seeking more approved obesity-drug options as it weighs providing weight-loss injections free through SUS.
- When
- The request to Anvisa was approved at the end of October 2026. Lula made the free-treatment promise in September.
- Where
- Brazil’s public health system, SUS.
- Why
- The ministry says the number of semaglutide injections approved for weight control remains limited, and wider availability could support the coverage assessment.
Brazil’s Health Ministry
Pharmaceutical industry figures
Public funding
Brazil’s Health Ministry
The ministry is seeking to include obesity injections in SUS and said it plans to reserve R$1.5 billion a year.
Pharmaceutical industry figures
Industry figures are skeptical that the proposed amount would cover treatment, given the high discounts that would be needed.
President Lula made free weight-loss injections through SUS a campaign promise.
Health Minister Alexandre Padilha asked Conitec to assess adding obesity injections to SUS.
The ministry’s request for Anvisa to accelerate reviews of obesity-drug registrations was approved.
- Semaglutide registrations
- 12 new medicines authorized for sale in 2026, all formally indicated for diabetes
- Price reductions
- New semaglutide versions are at least 35% cheaper
- Proposed annual budget
- R$1.5 billion
- Conitec review period
- 180 days, extendable by 90 days
- Previous rejection
- In August 2025, Conitec estimated Wegovy would cost R$6.8 billion over five years in SUS and serve some tens of thousands of patients
What people are saying
millions